Cargando…

PB2279: TRIAL IN PROGRESS: ODRONEXTAMAB, A CD20×CD3 BISPECIFIC ANTIBODY, FOR THE TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA (MZL) – A COHORT FROM THE ELM-2 STUDY

Detalles Bibliográficos
Autores principales: Cho, Seok-Goo, Kim, Tae Min, Taszner, Michał, Chen, Tsai Yun, Chaudhry, Aafia, Ufkin, Melanie, Uppala, Amulya, Sabir, Ayesha, Mohamed, Hesham, Ambati, Srikanth, Bachy, Emmanuel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429016/
http://dx.doi.org/10.1097/01.HS9.0000975848.41552.42